![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
Ranivisio (ranibizumab) is indicated for the treatment of neovascular (wet) age-related macular degeneration, treatment of visual impairment due to diabetic macular oedema or choroidal neovascularization, proliferative diabetic retinopathy, as well as visual impairment.
Lead Product(s): Ranibizumab
Therapeutic Area: Ophthalmology Product Name: Ranivisio
Highest Development Status: Approved Product Type: Large molecule
Recipient: Teva Pharmaceutical Industries
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
MHRA granted a licence for Ongavia® (ranibizumab), a biosimilar to Lucentis®*, for the treatment of (wet) age-related macular degeneration (AMD) and several other eye diseases, such as diabetic macular oedema and proliferative diabetic retinopathy.
Lead Product(s): Ranibizumab
Therapeutic Area: Ophthalmology Product Name: Ongavia
Highest Development Status: Approved Product Type: Large molecule
Recipient: Teva Pharmaceutical Industries
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
Details:
FYB201 (Ranibizumab) is used in treatment of various eye diseases in adults which cause damage to retina, thereby impairing vision. In these diseases, protein called VEGF causes excessive blood vessels to form within retina, resulting in a progressive loss of central vision.
Lead Product(s): Ranibizumab
Therapeutic Area: Ophthalmology Product Name: FYB201
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Formycon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2021
Details:
The aim of the randomized, double-blind, multi-center Phase III study is to demonstrate the comparability of FYB202 and the reference product Stelara(R) in terms of efficacy, safety and immunogenicity in patients with moderate to severe psoriasis vulgaris.
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: FYB202
Highest Development Status: Phase III Product Type: Large molecule
Recipient: Formycon
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020